Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.69
ARIA's Cash to Debt is ranked lower than
82% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ARIA: 0.69 )
Ranked among companies with meaningful Cash to Debt only.
ARIA' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 5.68 Max: 24.17
Current: 0.69
0.69
24.17
Equity to Asset -0.09
ARIA's Equity to Asset is ranked lower than
93% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARIA: -0.09 )
Ranked among companies with meaningful Equity to Asset only.
ARIA' s Equity to Asset Range Over the Past 10 Years
Min: -2.2  Med: 0.59 Max: 0.89
Current: -0.09
-2.2
0.89
F-Score: 5
Z-Score: -2.81
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -200.11
ARIA's Operating margin (%) is ranked lower than
60% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ARIA: -200.11 )
Ranked among companies with meaningful Operating margin (%) only.
ARIA' s Operating margin (%) Range Over the Past 10 Years
Min: -36749.1  Med: -941.11 Max: 58.61
Current: -200.11
-36749.1
58.61
Net-margin (%) -208.13
ARIA's Net-margin (%) is ranked lower than
61% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ARIA: -208.13 )
Ranked among companies with meaningful Net-margin (%) only.
ARIA' s Net-margin (%) Range Over the Past 10 Years
Min: -39582.8  Med: -983.50 Max: 47.63
Current: -208.13
-39582.8
47.63
ROE (%) -627.25
ARIA's ROE (%) is ranked lower than
97% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ARIA: -627.25 )
Ranked among companies with meaningful ROE (%) only.
ARIA' s ROE (%) Range Over the Past 10 Years
Min: -523.41  Med: -122.11 Max: -79.93
Current: -627.25
-523.41
-79.93
ROA (%) -30.73
ARIA's ROA (%) is ranked lower than
54% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ARIA: -30.73 )
Ranked among companies with meaningful ROA (%) only.
ARIA' s ROA (%) Range Over the Past 10 Years
Min: -120.13  Med: -80.44 Max: 92.14
Current: -30.73
-120.13
92.14
ROC (Joel Greenblatt) (%) -76.83
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ARIA: -76.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARIA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3088.06  Med: -988.95 Max: 1083.41
Current: -76.83
-3088.06
1083.41
Revenue Growth (3Y)(%) 43.40
ARIA's Revenue Growth (3Y)(%) is ranked higher than
89% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ARIA: 43.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARIA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.15 Max: 214.8
Current: 43.4
0
214.8
EBITDA Growth (3Y)(%) -4.70
ARIA's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. ARIA: -4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARIA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.2  Med: 3.70 Max: 36.2
Current: -4.7
-16.2
36.2
EPS Growth (3Y)(%) -2.30
ARIA's EPS Growth (3Y)(%) is ranked higher than
53% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARIA: -2.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARIA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.5  Med: -0.50 Max: 25.1
Current: -2.3
-18.5
25.1
» ARIA's 10-Y Financials

Financials (Next Earnings Date: 2016-02-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ARIA Guru Trades in Q4 2014

Paul Tudor Jones 27,227 sh (New)
Chuck Royce 440,602 sh (unchged)
Louis Moore Bacon 300,000 sh (unchged)
Stanley Druckenmiller Sold Out
George Soros Sold Out
Jim Simons 281,381 sh (-77.54%)
» More
Q1 2015

ARIA Guru Trades in Q1 2015

Joel Greenblatt 16,344 sh (New)
Michael Price 550,000 sh (New)
Jim Simons 2,675,481 sh (+850.84%)
Chuck Royce 375,352 sh (-14.81%)
Paul Tudor Jones 15,595 sh (-42.72%)
» More
Q2 2015

ARIA Guru Trades in Q2 2015

Michael Price 550,000 sh (unchged)
Chuck Royce 375,352 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 13,545 sh (-13.15%)
Jim Simons 2,094,481 sh (-21.72%)
» More
Q3 2015

ARIA Guru Trades in Q3 2015

Michael Price 716,500 sh (+30.27%)
Chuck Royce 375,352 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 23,639 sh (-98.87%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about ARIAD Pharmaceuticals Inc

Michael Price Invests in 11 Companies in First Quarter
Value investor Michael Price (Trades, Portfolio) is known for acquiring stock in out-of-favor small cap companies that are believed to be good values. His approach has paid off: Today, he manages MFP Investors, with $1.6 billion under management, much of it his own money. Read more...

Ratios

vs
industry
vs
history
P/S 10.95
ARIA's P/S is ranked lower than
54% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. ARIA: 10.95 )
Ranked among companies with meaningful P/S only.
ARIA' s P/S Range Over the Past 10 Years
Min: 1.73  Med: 62.25 Max: 1334
Current: 10.95
1.73
1334
Current Ratio 2.85
ARIA's Current Ratio is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ARIA: 2.85 )
Ranked among companies with meaningful Current Ratio only.
ARIA' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 4.07 Max: 15.1
Current: 2.85
0.62
15.1
Quick Ratio 2.84
ARIA's Quick Ratio is ranked lower than
61% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ARIA: 2.84 )
Ranked among companies with meaningful Quick Ratio only.
ARIA' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 3.96 Max: 14.95
Current: 2.84
0.52
14.95
Days Inventory 240.78
ARIA's Days Inventory is ranked lower than
77% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. ARIA: 240.78 )
Ranked among companies with meaningful Days Inventory only.
ARIA' s Days Inventory Range Over the Past 10 Years
Min: 8.07  Med: 28.46 Max: 48.84
Current: 240.78
8.07
48.84
Days Sales Outstanding 68.63
ARIA's Days Sales Outstanding is ranked lower than
53% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ARIA: 68.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARIA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.49  Med: 19.77 Max: 287.59
Current: 68.63
0.49
287.59
Days Payable 3.00
ARIA's Days Payable is ranked lower than
92% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. ARIA: 3.00 )
Ranked among companies with meaningful Days Payable only.
ARIA' s Days Payable Range Over the Past 10 Years
Min: 431.49  Med: 593.71 Max: 755.92
Current: 3
431.49
755.92

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.12
ARIA's Price/Median PS Value is ranked higher than
96% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. ARIA: 0.12 )
Ranked among companies with meaningful Price/Median PS Value only.
ARIA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 0.51 Max: 22.22
Current: 0.12
0.02
22.22
Price/Graham Number 2.13
ARIA's Price/Graham Number is ranked higher than
50% of the 286 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. ARIA: 2.13 )
Ranked among companies with meaningful Price/Graham Number only.
ARIA' s Price/Graham Number Range Over the Past 10 Years
Min: 0.17  Med: 0.90 Max: 7.14
Current: 2.13
0.17
7.14
Earnings Yield (Greenblatt) (%) -15.69
ARIA's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ARIA: -15.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARIA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 11.6  Med: 31.00 Max: 50.7
Current: -15.69
11.6
50.7

More Statistics

Revenue(Mil) $97
EPS $ -0.93
Beta1.64
Short Percentage of Float19.58%
52-Week Range $4.72 - 10.07
Shares Outstanding(Mil)189.29

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 115 222 274
EPS($) -1.28 -1.04 -0.93
EPS without NRI($) -1.28 -1.04 -0.93

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:APS.Germany, ARIA.Switzerland, 0R2K.UK,
Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors Feb 03 2016
ARIAD (ARIA) to Move AP32788 into Phase I/II Study in 2Q16 Feb 02 2016
ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results Feb 02 2016
Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial Feb 01 2016
ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788 Feb 01 2016
ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788 Feb 01 2016
Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Jan 27 2016
Coverage initiated on Ariad Pharm by Barclays Jan 19 2016
ARIAD Pharmaceuticals (ARIA) Stock Gets ‘Underweight’ Rating at Barclays Jan 19 2016
Ariad preps for a sale, but new chairman says it may take time Jan 19 2016
ARIAD Reports Inducement Grant to New Chief Executive Officer Jan 15 2016
Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 7.4% Jan 13 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 13 2016
Alex Denner on biotech selloff Jan 12 2016
ARIAD's Iclusig Regulatory Application Filed in Japan Jan 11 2016
ARIAD Announces Termination of Shareholder Rights Plan Jan 11 2016
ARIAD Announces Termination of Shareholder Rights Plan Jan 11 2016
ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors Jan 10 2016
ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors Jan 10 2016
ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib Jan 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK